IL117564A - Pharmaceutical and diagnostic compositions containing lysine derivatives - Google Patents

Pharmaceutical and diagnostic compositions containing lysine derivatives

Info

Publication number
IL117564A
IL117564A IL11756496A IL11756496A IL117564A IL 117564 A IL117564 A IL 117564A IL 11756496 A IL11756496 A IL 11756496A IL 11756496 A IL11756496 A IL 11756496A IL 117564 A IL117564 A IL 117564A
Authority
IL
Israel
Prior art keywords
pharmaceutical
compositions containing
diagnostic compositions
containing lysine
lysine derivatives
Prior art date
Application number
IL11756496A
Other languages
English (en)
Other versions
IL117564A0 (en
Original Assignee
Ct Molecular Med & Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Molecular Med & Immunology filed Critical Ct Molecular Med & Immunology
Publication of IL117564A0 publication Critical patent/IL117564A0/xx
Publication of IL117564A publication Critical patent/IL117564A/xx

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6895—Rescue therapy; Agonist-antagonist; Antidotes; Targeted rescue or protection, e.g. by folic acid-folinic acid or conjugated to antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL11756496A 1995-03-21 1996-03-20 Pharmaceutical and diagnostic compositions containing lysine derivatives IL117564A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/407,899 US5843894A (en) 1995-03-21 1995-03-21 Methods for reduced renal uptake of antibody fragments

Publications (2)

Publication Number Publication Date
IL117564A0 IL117564A0 (en) 1996-07-23
IL117564A true IL117564A (en) 2005-03-20

Family

ID=23614010

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11756496A IL117564A (en) 1995-03-21 1996-03-20 Pharmaceutical and diagnostic compositions containing lysine derivatives

Country Status (9)

Country Link
US (4) US5843894A (de)
EP (1) EP0767673B1 (de)
JP (1) JPH10505866A (de)
AT (1) ATE254469T1 (de)
CA (1) CA2190867C (de)
DE (1) DE69630761T2 (de)
ES (1) ES2211951T3 (de)
IL (1) IL117564A (de)
WO (1) WO1996029087A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843894A (en) * 1995-03-21 1998-12-01 Center For Molecular Medicine And Immunology Methods for reduced renal uptake of antibody fragments
JP2004510683A (ja) * 1999-06-07 2004-04-08 センター・フォー・モレキュラー・メディシン・アンド・イムノロジー 放射免疫療法において断片に付着されるα線エミッタまたはβ線エミッタ
WO2001005383A2 (en) * 1999-07-16 2001-01-25 Mallinckrodt, Inc. Inhibition of renal uptake of radiomolecules with a combination of lysine and arginine
EP1862172A1 (de) * 2006-05-31 2007-12-05 BioSynthema Inc. Zusammensetzung von einer Aminosäurelösung und Gelatine zur Hemmung renaler Aufnahme
WO2013106824A1 (en) * 2012-01-13 2013-07-18 Board Of Regents, The University Of Texas System Epherin receptor targeting agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283342A (en) * 1992-06-09 1994-02-01 Neorx Corporation Biotinylated small molecules
US4701521A (en) * 1978-07-17 1987-10-20 The Trustees Of Boston University Method of effecting cellular uptake of molecules
US5595734A (en) * 1988-04-06 1997-01-21 Alfacell Corporation Compositions comprising ONCONASE (tm) and lovastatin
DE69026387T2 (de) * 1989-09-29 1996-11-28 Neorx Corp., Seattle, Wash. Reduktion der nichtzielspezifischen retention von immunokonjugaten und ihren metaboliten
US5225180A (en) * 1991-09-10 1993-07-06 Diatech, Inc. Technetium-99m labeled somatostatin-derived peptides for imaging
US5843894A (en) * 1995-03-21 1998-12-01 Center For Molecular Medicine And Immunology Methods for reduced renal uptake of antibody fragments
US5840296A (en) * 1997-10-15 1998-11-24 Raines; Ronald T. Engineered cytotoxic ribonuclease A

Also Published As

Publication number Publication date
US5843894A (en) 1998-12-01
EP0767673B1 (de) 2003-11-19
US20030203836A1 (en) 2003-10-30
CA2190867A1 (en) 1996-09-26
AU5361696A (en) 1996-10-08
EP0767673A1 (de) 1997-04-16
IL117564A0 (en) 1996-07-23
AU700346B2 (en) 1999-01-07
ES2211951T3 (es) 2004-07-16
DE69630761T2 (de) 2004-09-23
JPH10505866A (ja) 1998-06-09
DE69630761D1 (de) 2003-12-24
ATE254469T1 (de) 2003-12-15
CA2190867C (en) 2009-06-02
US20020111300A1 (en) 2002-08-15
US20060182683A1 (en) 2006-08-17
WO1996029087A1 (en) 1996-09-26
EP0767673A4 (de) 1999-08-04

Similar Documents

Publication Publication Date Title
DE69713526D1 (de) Lösliche prodrugs von paclitaxel
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
JPH09508141A (ja) ビタミンb▲下12▼とタンパク質との複合体
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
IL121160A0 (en) Method compositions and kits for increasing the oral bioavailability of pharmaceutical agents
BG101118A (en) Therapeutical compounds
EP0701448A4 (de) Erweiterung des vitamin b 12 - aufnahmesystems unter verwendung von polymeren
BR0112591A (pt) Derivados de acridina e sua aplicação como medicamento
DE69829175D1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zubereitungen
AU2905092A (en) Pharmaceutical dipeptide compositions and methods of use thereof
ES2173641T3 (es) Composicion de derivados opiaceos para la fabricacion de medicamentos.
CA2336945A1 (en) Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
WO1992019213A3 (en) Enhancement of abnormal tissue uptake of antibodies, tumor-specific agents or conjugates thereof for diagnostic imaging or therapy
EE04606B1 (et) H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks
WO1996024370B1 (en) Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin
KR970025615A (ko) 암 전이 억제제
DE69125715D1 (de) Heterozyklische verbindungen
TR200101163T2 (tr) Safra suyu ikameli fenil-alkenoilguanidinler, üretim yöntemleri, kullanımları
ATE196768T1 (de) Neue 6-hydroxy und 6-oxo-androstan verbindungen mit kardioaktivität und pharmazeutische präparate davon
CA2038744A1 (en) Pharmaceutical composition containing slightly water-soluble drug
NO330913B1 (no) Konjugeringsprodukt, dets anvendelse og farmasoytisk preparat inneholdende det samme.
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
NO20001828D0 (no) Metode for å forhindre nefrotoksisitet forårsaket av cyklosporiner og tacrolimus
NO20042055L (no) Tymosinalfa 1-peptid/polymerkonjugater
IL117564A0 (en) Pharmaceutical and diagnostic compositions containing lysine derivatives

Legal Events

Date Code Title Description
FF Patent granted